Caribou Biosciences outlined its plan to widen access to allogeneic CAR T therapies, moving toward a pivotal Phase III study. The company said its allogeneic approach has shown durability comparable to approved autologous CAR T therapies in certain blood cancers, supported by gene-editing strategies intended to reduce off-target effects and improve persistence. Caribou’s messaging focused on logistics and eligibility constraints: it argued that 75% to 90% of patients eligible for CAR T do not receive it, citing rapid disease progression, manufacturing delays, and socioeconomic and insurance barriers. The company said it can dose patients off the shelf without bespoke manufacturing waits. For the field, a pivotal Phase III push for an allogeneic model signals a direct attempt to restructure CAR T capacity constraints and manufacturing bottlenecks.